Efruxifermin
| Clinical data | |
|---|---|
| Other names | AKR-001; AMG-876 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| UNII | |
Efruxifermin (AKR-001) is a fibroblast growth factor 21 (FGF21) analog developed to treat nonalcoholic steatohepatitis and type 2 diabetes.[1][2][3]
References[edit]
- ^ Shao, Weijuan; Jin, Tianru (March 2022). "Hepatic hormone FGF21 and its analogues in clinical trials". Chronic Diseases and Translational Medicine. 8 (1): 19–25. doi:10.1016/j.cdtm.2021.08.005. ISSN 2589-0514. PMC 9126297. PMID 35620160.
- ^ Carvalho, Thiago (20 June 2023). "Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH". Nature Medicine. 29 (8): 1881. doi:10.1038/d41591-023-00055-1. PMID 37340082. S2CID 259210572.
- ^ Kaufman, Allegra; Abuqayyas, Lubna; Denney, William S.; Tillman, Erik J.; Rolph, Tim (July 2020). "AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients". Cell Reports Medicine. 1 (4): 100057. doi:10.1016/j.xcrm.2020.100057. PMC 7659583. PMID 33205064.